Carlsmed announced it raised $38.5 Million in an initial filing from an offering of $52.5 Million

Company

Location

About

Carlsmed’s mission is to improve outcomes and decrease the cost of healthcare for spine surgery. The company’s aprevo® devices are designed to improve the standard of care for surgical treatment of patients with adult spinal malalignment. Carlsmed uses patient data and proprietary digital technologies to create optimal surgical plans and personalized aprevo® spine fusion devices for each patient. The Carlsmed® aprevo® devices are FDA cleared and have been granted FDA Breakthrough Designation, an industry first for any implanted device, and are commercially available in the U.S.